PLX Protalix BioTherapeutics
Protalix BioTherapeutics earnings company data as of 4:47 AM ET 10/22
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by PLX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $101K bought by 1 insider
- $314 sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Dror Bashan CEOBuy$101K 56,000 shares at $1.81 +42% to stakeTraded Dec 19, 2025 Filed Dec 23, 2025
-
Amos Bar-Shalev DirectorSale$314 168 shares at $1.87 100% of stakeTraded Nov 18, 2025 Filed Nov 19, 2025
SEC filings
Recent issuer filings from EDGAR, 21 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.